PrimeRFP SCOUT · Federal Contract Recompete Brief

75N91018F00071Hhsn261201500003i; hhsn26100071 — Leidos Biomedical Research, Inc

Leidos Biomedical Research, Inc holds $2.1B across 186 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 4 related awards under parent HHSN261201500003I. Recompete timing centers on the Aug 31, 2027 PoP end — agencies typically plan 12–18 months ahead.

Nih Nci

Awarding office

Leidos Biomedical Research, Inc

Recipient

Aug 31, 2027

PoP end

$38.7M

Obligated

561210

NAICS

M1HA

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Leidos Biomedical Research, Inc — $90

Contract facts

Federal

Contract number75N91018F00071

Also listed asHHSN261201500003I-75N91018F00071

AgencyNih Nci

Awarding officeNih Nci

IncumbentLeidos Biomedical Research, Inc

UEIHV8BH9BPG8Y9

NAICS561210

No full NAICS 561210 intel page yet. Browse NAICS intelligence

PSCM1HA

Parent IDIQ / IDVHHSN261201500003I

Place of performanceFREDERICK, MD

Related solicitationN01CO5240180

PoP end (current)Aug 31, 2027

Obligated$38.7M

HHSN261201500003I; HHSN26100071; 400.021.0071.0001; NCI CBIIT; APPROPRIATED; EXPAND DATA COMMONS; 09/14/18-09/13/23 is a federal award for Nih Nci held by Leidos Biomedical Research, Inc. Estimated value $67M ($38.7M obligated). Current period of performance ends Aug 31, 2027. Place of performance: FREDERICK, MD. Related solicitation N01CO5240180.

HHSN261201500003I; HHSN26100071; 400.021.0071.0001; NCI CBIIT; APPROPRIATED; EXPAND DATA COMMONS; 09/14/18-09/13/23

Recompete timing

Public

● Expiring in 376 days

Current PoP ends Aug 31, 2027 (376 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Incumbent footprint

Public record

Leidos Biomedical Research, Inc — $2.1B obligated across 186 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$2.1B · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

HHSN26100039

RETROSPECTIVE TUMOR CHARACTERIZATION ANALYSIS (MOONSHOT)

Department of Health and Human Services (HHS) · LEIDOS BIOMEDICAL RESEARCH, INC.

$21.3M

Sep 30, 2026

75N91018F00073

PDX PANELS FROM COMMON TUMORS

Department of Health and Human Services (HHS) · LEIDOS BIOMEDICAL RESEARCH, INC.

$67.9M

Sep 25, 2027

75N91018F00059

EBOLA VIRUS AND OTHER INFECTIOUS DISEASES

Department of Health and Human Services (HHS) · LEIDOS BIOMEDICAL RESEARCH, INC.

$64.9M

Sep 21, 2028

75N91018F00077

CELL-BASED IMMUNOTHERAPY PRODUCTS

Department of Health and Human Services (HHS) · LEIDOS BIOMEDICAL RESEARCH, INC.

$53.5M

Aug 29, 2029

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75N91018F00071?

75N91018F00071 (Hhsn261201500003i; hhsn26100071) is a Nih Nci award with an estimated value of $67M, currently held by Leidos Biomedical Research, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N91018F00071?

Nih Nci awarded 75N91018F00071 to Leidos Biomedical Research, Inc.

Who is the incumbent on 75N91018F00071?

Leidos Biomedical Research, Inc is the incumbent with $2.1B across 186 related awards in SCOUT’s public footprint. The current period of performance ends Aug 31, 2027.

When does Leidos Biomedical Research, Inc’s 75N91018F00071 come up for recompete?

SCOUT tracks a period-of-performance end of Aug 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action May 1, 2025